← 返回

原发性胃肠道 T 细胞淋巴瘤与惰性淋巴增殖性疾病:实用诊断与治疗策略

英文原题:Primary Gastrointestinal T-Cell Lymphoma and Indolent Lymphoproliferative Disorders: Practical Diagnostic and Treatment Approaches.

查看英文原题

Primary Gastrointestinal T-Cell Lymphoma and Indolent Lymphoproliferative Disorders: Practical Diagnostic and Treatment Approaches.

PubMed 2021/11/18(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

原发性胃肠道(GI)T细胞肿瘤极为罕见,是一组异质性疾病,具有各自不同的临床病理特征。鉴于不同亚型预后差异显著,即使发病率低,临床医生和病理学家也必须了解这些肿瘤的关键特征。最常见的两种侵袭性原发性GI T细胞淋巴瘤是肠病相关T细胞淋巴瘤和单形性亲上皮性肠道T细胞淋巴瘤。此外,鼻型结外NK/T细胞淋巴瘤和间变性大细胞淋巴瘤也可能原发于GI道或继发累及GI道。在世界卫生组织第4版修订分类中,胃肠道惰性T细胞淋巴增殖性疾病被列为暂定实体。本综述总结这些疾病实体最新的临床病理特征,包括原发性GI T细胞淋巴瘤和惰性淋巴增殖性疾病的分子特征,重点介绍既有综述尚未总结的最新治疗方法。此外,我们全面回顾现有文献,探讨以下问题:病理学家如何区分临床预后不同的亚型?如何区分原发性GI肿瘤和继发累及?早期如何将这些肿瘤与非特异性炎性改变区分开来?

展开英文摘要原文

Primary gastrointestinal (GI) T-cell neoplasms are extremely rare heterogeneous disease entities with distinct clinicopathologic features. Given the different prognoses of various disease subtypes, clinicians and pathologists must be aware of the key characteristics of these neoplasms, despite their rarity. The two most common aggressive primary GI T-cell lymphomas are enteropathy-associated T-cell lymphoma and monomorphic epitheliotropic intestinal T-cell lymphoma.

In addition, extranodal natural killer (NK)/T-cell lymphoma of the nasal type and anaplastic large cell lymphoma may also occur in the GI tract or involve it secondarily. In the revised 4th World Health Organization classification, indolent T-cell lymphoproliferative disorder of the GI tract has been incorporated as a provisional entity. In this review, we summarize up-to-date clinicopathological features of these disease entities, including the molecular characteristics of primary GI T-cell lymphomas and indolent lymphoproliferative disorders.

We focus on the latest treatment approaches, which have not been summarized in existing reviews.

Further, we provide a comprehensive review of available literature to address the following questions: How can pathologists discriminate subtypes with different clinical prognoses? How can primary GI neoplasms be distinguished from secondary involvement? How can these neoplasms be distinguished from non-specific inflammatory changes at an early stage?

论文信息

作者
Nishimura MF、Nishimura Y、Nishikori A、Yoshino T、Sato Y
单位
Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan.Japan
文献类型
综述
期刊
Cancers2021 Nov 18
原文标识
PubMed 34830926 · DOI 10.3390/cancers13225774